The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer.
We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry.
The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05).
Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).
Saykin AJ, de Ruiter MB, McDonald BC, Deprez S, Silverman DH (2013) Neuroimaging biomarkers and cognitive function in non-CNS cancer and its treatment: current status and recommendations for future research. Brain Imaging Behav 7(4):363–373. https://doi.org/10.1007/s11682-013-9283-7CrossRefPubMedPubMedCentral
Simo M, Rifa-Ros X, Rodriguez-Fornells A, Bruna J (2013) Chemobrain: a systematic review of structural and functional neuroimaging studies. Neurosci Biobehav Rev 37(8):1311–1321. https://doi.org/10.1016/j.neubiorev.2013.04.015CrossRefPubMed
Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20–37. https://doi.org/10.1634/theoncologist.12-1-20CrossRefPubMed
McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2012) Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 30(20):2500–2508. https://doi.org/10.1200/JCO.2011.38.5674CrossRefPubMedPubMedCentral
McDonald BC, Conroy SK, Smith DJ, West JD, Saykin AJ (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30 Suppl:S117–S125. https://doi.org/10.1016/j.bbi.2012.05.007
Lepage C, Smith AM, Moreau J, Barlow-Krelina E, Wallis N, Collins B, MacKenzie J, Scherling C (2014) A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus 3:444. https://doi.org/10.1186/2193-1801-3-444CrossRefPubMedPubMedCentral
Chen BT, Sethi SK, Jin T, Patel SK, Ye N, Sun CL, Rockne RC, Haacke EM, Root JC, Saykin AJ, Ahles TA, Holodny AI, Prakash N, Mortimer J, Waisman J, Yuan Y, Somlo G, Li D, Yang R, Tan H, Katheria V, Morrison R, Hurria A (2018) Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study. Breast Cancer Res 20(1):38. https://doi.org/10.1186/s13058-018-0965-3CrossRefPubMedPubMedCentral
Ashburner J, Friston KJ (2009) Computing average shaped tissue probability templates. Neuroimage 45(2):333–341. https://doi.org/10.1016/j.neuroimage.2008.12.008CrossRefPubMed
Ashburner J (2009) Computational anatomy with the SPM software. Magn Reson Imaging 27(8):1163–1174. https://doi.org/10.1016/j.mri.2009.01.006CrossRefPubMed
Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, Carlozzi NE, Slotkin J, Blitz D, Wallner-Allen K, Fox NA, Beaumont JL, Mungas D, Nowinski CJ, Richler J, Deocampo JA, Anderson JE, Manly JJ, Borosh B, Havlik R, Conway K, Edwards E, Freund L, King JW, Moy C, Witt E, Gershon RC (2013) Cognition assessment using the NIH toolbox. Neurology 80(11 Suppl 3):S54–S64. https://doi.org/10.1212/WNL.0b013e3182872dedCrossRefPubMedPubMedCentral
Li M, Caeyenberghs K (2018) Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev 92:304–317. https://doi.org/10.1016/j.neubiorev.2018.05.019CrossRefPubMed
Kesler SR, Kent JS, O’Hara R (2011) Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 68(11):1447–1453. https://doi.org/10.1001/archneurol.2011.245CrossRefPubMedPubMedCentral
Lopez Zunini RA, Scherling C, Wallis N, Collins B, Mackenzie J, Bielajew C, Smith AM (2013) Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav 7(4):460–477. https://doi.org/10.1007/s11682-012-9213-0CrossRefPubMed
Andryszak P, Wilkosc M, Izdebski P, Zurawski B (2017) A systemic literature review of neuroimaging studies in women with breast cancer treated with adjuvant chemotherapy. Contemp Oncol 21(1):6–15. https://doi.org/10.5114/wo.2017.66652
Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S, Welsh RC (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32(3):324–331. https://doi.org/10.1080/13803390903032537CrossRefPubMed
- Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer
Bihong T. Chen
Sunita K. Patel
Russell C. Rockne
James C. Root
Andrew J. Saykin
Tim A. Ahles
Andrei I. Holodny
- Springer US
- Breast Cancer Research and Treatment
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
Neu im Fachgebiet Onkologie
Mail Icon II